Editorial: Predictive Imagable Biomarkers for Neurodegenerative and Neurodevelopmental Diseases. Identifying Factor for Brain Microenvironment Changes is required
- 1National Brain Research Centre (NBRC), India
- 2Florey Institute of Neuroscience and Mental Health, Australia
- 3Department of Medicine, Haukeland University Hospital, Norway
In the last four decades, tremendous economic and technological development has helped to improve the quality of life and average life span has increased substantially. As a consequence, the number of people with much higher age is increasing and reports of aging associated disorders are multiplying due to various neurodegenerative disorders such as Alzheimer’s, Parkinson’s frontotemporal, dementia with Lewy body disease etc. The causal process of these neurodegenerative disorders is not known yet; however, oxidative stress is recognized to play an important role [1; 2; 3]. At the same time, the number of cases with neurodevelopmental disorders (Autism Spectrum Disorders (ASD) , Epilepsy  and Attention Deficit Hyperactivity Disorder ) is increasing rapidly in the early part of the life due to multifactorial reasons. Two major health related issues in two distinct age groups need urgent attention to identify the causal process and subsequently a therapeutic development for cure.
The advancements in different imaging techniques (e.g. Magnetic Resonance Imaging (MRI), MR Spectroscopy (MRS), functional MRI (fMRI), functional MRS, Magnetic Encephalography, Diffusion Tensor Imaging etc.) provide various critical features for reliably predicting the individuals who will progress from asymptomatic pre-clinical phase to clinical phases.
In this context, it is critical to investigate the factors which may impact the brain microenvironment these could trigger the early causal processes. In neurodevelopmental and neurodegenerative disorders, the roles of various neurochemicals receptors or antioxidants and their abnormal modulations are getting huge attention for more in-depth research. Recently it was discovered that brain microenvironment has the role to modulate the two distinct conformations of glutathione (GSH), a major antioxidant involved in neutralizing harmful radicals. GSH exists in two conformational states (extended and closed form) in the brain [7; 8; 9 ]. It is therefore paramount to identify novel imagable diagnostic biomarkers involving antioxidants, neurotransmitters and physiological parameters that can aid in discovering the causal processes of these brain disorders and can be translated into clinical practices for simplified diagnostic tests and advocating appropriate lifestyle changes to delay the onset of symptoms.
This special issue has a total ten articles from various laboratories. Mandal and co-workers have developed a Hadoop-based big data framework (BHARAT) integrating non-invasive MRI, MRS as well as neuropsychological test outcomes to identify early diagnostic biomarkers of AD. The framework for AD incorporates the three “V”s (volume, variety and velocity) with advanced data mining, machine learning, and statistical modelling algorithms .
Feng and co-workers have used corpus callosum (CC) radiomic features related to the diagnosis of AD. They have aimed to identify the CC radiomic features related to the diagnosis of AD and build classification model based on machine learning for the diagnosis of AD .
Teipel and his group have used MRI and cognitive data from 124 patients, derived from ANDI-1 cohort (follow up period 0.4 – 3.1 years). They conclude that basal forebrain volume, but not hippocampus volume, is a significant predictor of rates for global cognitive decline to predict subsequent cognitive decline during cholinergic treatment .
Yamasakhi and co-worker have studied the driving ability in the Alzheimer’s Disease Spectrum (ADS) and have hypothesized that feasibility of event-related potentials can be a possible predictive biomarker of driving ability in ADS. Interestingly, even in the early stage of the disease, patients with ADS are characterized by the impairment of visuospatial function such as radial optic flow perception related to self-motion perception .
Oishi and co-workers, using functional MRI, found a significant relationship between low Grey Matter (GM) volume in the right inferior parietal lobule (IPL) and severity of mental disorientation. They hypothesize that right IPL is responsible for mental disorientation in amnestic MCI (aMCI) based on voxel-based morphometry. A significant decreased GM volume has been found in the right IPL, which correlates with lower orientation scores on the COGNISTAT cognitive testing tool .
O'Gorman Tuura and co-worker have investigated the relationship between the axial symptoms of PD and GABA and glutamate levels have quantified using MRS (PD patients N=20 PD and 17 healthy control). The study showed associations between GABA and Glx and axial symptoms scores are typically more prominent in akinetic-rigid patients than in tremor-dominant patients .
Emamzadeh and co-worker have presented various risk factors for PD and PD treatment options. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects. Conventional pharmacological treatment of PD is based on the replacement of dopamine using dopamine precursors (levodopa, L-DOPA, L-3,4 dihydroxyphenylalanine), dopamine agonists (amantadine, apomorphine) and MAO-B inhibitors (selegiline, rasagiline), which can be used alone or in combination with each other .
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative process affecting upper and lower motor neurons as well as non-motor systems. Wirth and corworkers report the precentral and postcentral cortical thinning detected by structural MRI combined with clinical (ALS-specific functional rating scale revised, ALSFRS-R) and neurophysiological (motor unit number index, MUNIX) biomarkers in both cross-sectional and longitudinal analyses. Their study concludes that a combinatory use of structural MRI, neurophysiological and clinical biomarkers allows for an appropriate and detailed assessment of clinical state and course of disease of ALS .
Dwyer and co-workers have reported that no significant changes in GABA, Glx, or NAA levels are observed as a result of anodal stimulation, or between active and sham stimulation, suggesting that a single session of anodal tDCS to the pSTG may be less effective than in other cortical areas .
Winklewski and co-workers report that DTI can reveal strategic information with respect to white matter tracts, disconnection mechanisms, and related symptoms. Axial and radial diffusivity are likely to provide quite consistent information in healthy subjects, and in pathological conditions with limited edema and inflammatory changes. DTI remains one of the most promising non-invasive diagnostic tools in medicine .
It is our sincere efforts to bring the latest research from leading laboratories to enrich the area, and we believe that multi-centric research collaboration could immensely help to identify various factors responsible for brain microenvironment changes. These critical features can be used in big data analytics, and it should subsequently help in setting a successful clinical trial .
Keywords: Imagable Biomarkers, neurodevelopmental, neurodegenerative, Glutathione, imaging techniques
Received: 13 May 2019;
Accepted: 17 May 2019.
Edited by:Jan Kassubek, University of Ulm, Germany
Reviewed by:Hans-Peter Müller, University of Ulm, Germany
Copyright: © 2019 Mandal and Ersland. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Pravat K. Mandal, National Brain Research Centre (NBRC), Gurgaon, India, email@example.com